High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 21, Issue 11, Pages 1318-1325
Publisher
Springer Nature
Online
2015-10-19
DOI
10.1038/nm.3954
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
- (2015) Kyriakos P. Papadopoulos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
- (2015) Berglind O. Einarsdottir et al. Oncotarget
- Molecular Characterization of Patient-Derived Human Pancreatic Tumor Xenograft Models for Preclinical and Translational Development of Cancer Therapeutics
- (2015) Mike Mattie et al. NEOPLASIA
- Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
- (2014) G. V. Scagliotti et al. ANNALS OF ONCOLOGY
- Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology
- (2014) Edward Rosfjord et al. BIOCHEMICAL PHARMACOLOGY
- A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
- (2014) I Brana et al. BRITISH JOURNAL OF CANCER
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
- (2014) S. Di Cosimo et al. CLINICAL CANCER RESEARCH
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
- (2014) Peter Eirew et al. NATURE
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
- (2013) D. Siolas et al. CANCER RESEARCH
- Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
- (2013) S. A. Flanigan et al. CLINICAL CANCER RESEARCH
- Clinical Approval Success Rates for Investigational Cancer Drugs
- (2013) J A DiMasi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
- (2013) K. Friedbichler et al. MOLECULAR CANCER THERAPEUTICS
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Phase II and Phase III attrition rates 2011–2012
- (2013) John Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS -Mutant Lung Cancer
- (2013) Miriam Molina-Arcas et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
- (2012) S. Julien et al. CLINICAL CANCER RESEARCH
- A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff
- (2012) Pablo Cingolani et al. FLY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV
- (2011) Jarupon Fah Sathirapongsasuti et al. BIOINFORMATICS
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- (2011) Hiromichi Ebi et al. JOURNAL OF CLINICAL INVESTIGATION
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- (2011) Mark A DePristo et al. NATURE GENETICS
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
- (2011) Yoko S DeRose et al. NATURE MEDICINE
- Phase II failures: 2008–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts
- (2011) Patrick T. Hennessey et al. PLoS One
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
- (2010) L de Plater et al. BRITISH JOURNAL OF CANCER
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- Genome remodelling in a basal-like breast cancer metastasis and xenograft
- (2010) Li Ding et al. NATURE
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- Meenhard Herlyn
- (2010) Ruth Halaban Pigment Cell & Melanoma Research
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- Synergistic drug combinations tend to improve therapeutically relevant selectivity
- (2009) Joseph Lehár et al. NATURE BIOTECHNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started